🇺🇸 FDA
Pipeline program

REX-001

REX-001-004

Phase 3 small_molecule terminated

Quick answer

REX-001 for Peripheral Arterial Disease (PAD) is a Phase 3 program (small_molecule) at Design Therapeutics with 2 ClinicalTrials.gov record(s).

Program details

Company
Design Therapeutics
Indication
Peripheral Arterial Disease (PAD)
Phase
Phase 3
Modality
small_molecule
Status
terminated

Clinical trials